ArticleScientific reports2025
Design of highly sensitive refractive index biosensor with cobalt-glass materials for detection of glucose concentration in blood.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes represents a conceivably fatal condition that occurs because of elevated blood glucose levels. The surface plasmon resonance (SPR) biosensor has emerged as currently the most sophisticated method for determining glucose levels. The blood glucose biosensor performance is determined by the refraction coefficient of the substance containing glucose in the form of molecules. In this study, we have offered Hollow-Ring Cubic-Structured Refractive Index Biosensor (HRCSRIB) for monitoring glucose levels in blood from normal concentrations of 165 to 180 (mg/dL) in compared to diabetic glucose concentrations of 182, 205, 220, 240, 255, 289, 255 (mg/dL). This biosensor detects variations in the refractive index of urine, which correlate with changes in blood glucose concentration. The presented biosensing technology uses cobalt compounds and their unique structure to analyze blood glucose levels by measuring the urine refractive value. The study of various parameters associated with geometrical shape dimensions has been also represented. This offered biosensor has an exceptional sensitivity with 1750 nm/RIU, and a detection limit of 0.000410. The exceptional value of the quality factor, as well as the figure of merit value, is 1670.07 nm/RIU for 182 mg/dL and 1241.13 for 205-289 mg/dL respectively. The best transmittance response of 6%, 9%, 4%, and 32% has been obtained. The aforementioned sensor's distinctive characteristics facilitate its biomedical applications as an optical on-chip sensor that monitors level of glucose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.